REG - Hutchmed China Ltd - Announcement on Results of Annual General Meeting

HUTCHMED (China)Announcement

12/05/2026 12:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260512:nRSL0151Ea&default-theme=true

RNS Number : 0151E  Hutchmed (China) Limited  12 May 2026

 

Annual General Meeting held on May 12, 2026 - Poll Results

 

 

Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, May 12, 2026: HUTCHMED
(China) Limited ("HUTCHMED (https://www.hutch-med.com/) " or the "Company")
(Nasdaq/AIM: HCM; HKEX:13) today announces that all ordinary resolutions and
special resolution put to its Annual General Meeting ("AGM") held on May 12,
2026 were duly passed. The poll results of the resolutions were as follows:

 

 

                                                                                               Number of Votes (%)*

                                                                                                                                   Passed by Shareholders

 Ordinary Resolutions

              For                                                                              Against      Withheld(#)

 1.           To consider and adopt the audited Financial Statements, and the Directors¡¦      440,149,560  1,020         36,866   Yes
              Report and the Independent Auditors¡¦ Report for the year ended December 31,

              2025.                                                                            (99.9998%)   (0.0002%)

 2(A).        To re-elect Dr Dan ELDAR as a Director.                                          409,558,086  30,601,245    26,615   Yes

                                                                                               (93.0477%)   (6.9523%)

 2(B).        To re-elect Dr Weiguo SU as a Director.                                          413,398,701  26,768,655    18,590   Yes

                                                                                               (93.9185%)   (6.0815%)

 2(C).        To re-elect Mr CHENG Chig Fung, Johnny as a Director.                            410,525,379  29,642,001    18,566   Yes

                                                                                               (93.2657%)   (6.7343%)

 2(D).        To re-elect Ms Edith SHIH as a Director.                                         426,101,060  14,066,301    18,585   Yes

                                                                                               (96.8043%)   (3.1957%)

 2(E).        To re-elect Ms Ling YANG as a Director.                                          428,114,519  12,052,842    18,585   Yes

                                                                                               (97.2618%)   (2.7382%)

 2(F).        To re-elect Dr Renu BHATIA as a Director.                                        436,786,545  3,380,786     18,615   Yes

                                                                                               (99.2319%)   (0.7681%)

 2(G).        To re-elect Dr Chaohong HU as a Director.                                        440,122,580  44,806        18,560   Yes

                                                                                               (99.9898%)   (0.0102%)

 2(H).        To re-elect Professor TAN Shao Weng, Daniel as a Director.                       440,141,241  26,130        18,575   Yes

                                                                                               (99.9941%)   (0.0059%)

 2(I).        To re-elect Mr WONG Tak Wai as a Director.                                       440,128,120  39,265        18,561   Yes

                                                                                               (99.9911%)   (0.0089%)

 3.           To re-appoint PricewaterhouseCoopers and PricewaterhouseCoopers Zhong Tian LLP   394,937,813  45,204,596    43,537   Yes
              as Independent Auditors for Hong Kong financial reporting and US financial

              reporting purposes, respectively, and to authorize the Directors to fix the      (89.7296%)   (10.2704%)
              Auditors¡¦ remuneration.

 Special Resolution
 4.           To grant a general mandate to the Directors to issue additional shares of the    440,097,496  65,548        22,902   Yes

            Company.^

                                                                                (99.9851%)   (0.0149%)

 Ordinary Resolutions
 5.           To grant a general mandate to the Directors to repurchase shares of the          440,120,461  29,603        35,382   Yes
              Company.^

                                                                                (99.9933%)   (0.0067%)

 6.           To approve the adoption of 2026 Share Option Scheme of the Company.^             396,856,980  43,306,320    22,146   Yes

                                                                                               (90.1613%)   (9.8387%)

 

*  Percentages rounded to 4 decimal places.

(#) A vote withheld is not a vote in law and is not counted in the calculation
of the proportion of the votes for or against a resolution.

^ The full text of Resolutions 4, 5 and 6 are set out in the notice of AGM
dated April 10, 2026.

 

Notes:

 

(1)       Except for Ms Ling YANG and Professor MOK Shu Kam, Tony who
had prior overseas work commitments and were unable to attend the AGM, all
Directors of the Company, namely Dr Dan ELDAR, Dr Weiguo SU, Mr CHENG Chig
Fung, Johnny, Ms Edith SHIH, Dr Renu BHATIA, Dr Chaohong HU, Professor TAN
Shao Weng, Daniel and Mr WONG Tak Wai, attended the AGM, either in person or
by means of electronic facilities.

 

(2)       Number of shares entitling the holders to attend and vote on
the resolution at the AGM: 872,335,120 shares, being the total number of
issued shares of the Company.  The Company did not hold any treasury shares
(including any treasury shares held or deposited with Central Clearing and
Settlement System) as at the AGM date.

 

(3)       Number of shares entitling the holders to attend and abstain
from voting in favor as set out in Rule 13.40 of the Rules Governing the
Listing of Securities on The Stock Exchange of Hong Kong Limited (the
¡§Listing Rules¡¨) at the AGM: Nil.

 

(4)       Number of shares for holders required under the Listing Rules
to abstain from voting at the AGM: Nil.

 

(5)       The scrutineer for the poll at the AGM was Computershare
Investor Services (Jersey) Limited, the Principal Share Registrar of the
Company.

 

 

About HUTCHMED

 

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage,
biopharmaceutical company. Іt is committed to the discovery, global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. Since inception it has
focused on bringing drug candidates from in-house discovery to patients around
the world, with its first three medicines marketed in China, and the first of
which is also approved around the world including in the US, Europe and Japan.
For more information, please visit: www.hutch‑med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

 

CONTACTS

 

 Investor Enquiries                                  +852 2121 8200 /

                                                   ir@hutch-med.com (mailto:ir@hutch-med.com)

 Media Enquiries
 FTI Consulting ¡V                                   +44 20 3727 1030 / HUTCHMED@fticonsulting.com
                                                     (mailto:HUTCHMED@fticonsulting.com)
 Ben Atwell / Tim Stamper                            +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
 Brunswick ¡V Zhou Yi                                +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                     (mailto:HUTCHMED@brunswickgroup.com)

 Panmure Liberum                                     Nominated Advisor and Joint Broker
 Atholl Tweedie / Emma Earl / Rupert Dearden         +44 20 7886 2500

 Cavendish                                           Joint Broker
 Geoff Nash / Nigel Birks                            +44 20 7220 0500

 Deutsche Numis                                      Joint Broker
 Freddie Barnfield / Jeffrey Wong / Duncan Monteith  +44 20 7260 1000

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGMZGMKMZLGVZM



            Copyright 2019 Regulatory News Service, all rights reserved